AngioDynamics (ANGO) Projected to Post Earnings on Wednesday

AngioDynamics (NASDAQ:ANGO) is anticipated to release its earnings data before the market opens on Wednesday, April 2nd. Analysts expect AngioDynamics to post earnings of ($0.13) per share and revenue of $70.30 million for the quarter. AngioDynamics has set its FY 2025 guidance at -0.380–0.340 EPS and its FY25 guidance at ($0.38)-($0.34) EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. AngioDynamics’s revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.05) earnings per share. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Stock Performance

Shares of AngioDynamics stock opened at $9.50 on Monday. The firm has a fifty day moving average of $10.41 and a two-hundred day moving average of $8.81. The stock has a market capitalization of $384.43 million, a price-to-earnings ratio of -1.69 and a beta of 0.56. AngioDynamics has a 52 week low of $5.47 and a 52 week high of $13.50.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the transaction, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.40% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright increased their target price on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.